Bioadaptives (BDPT) Common Equity (2013 - 2026)

Bioadaptives has disclosed Common Equity across 13 years of filings, most recently posting -$2.1 million for Q1 2026.

• Common Equity for Q1 2026 came in at -$2.1 million, down 35.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.1 million (down 35.97% YoY), and the FY2025 annual result was -$2.1 million, down 45.5% from the prior year.
• Common Equity came in at -$2.1 million for Q1 2026 at Bioadaptives, roughly flat from -$2.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$1.1 million in Q3 2023 to a low of -$2.1 million in Q1 2026.
• The 5-year median for Common Equity is -$1.6 million (2022), against an average of -$1.6 million.
• Across the five-year window, Common Equity slumped 57.56% in 2024 and surged 34.07% in 2025, its largest moves.
• Bioadaptives' Common Equity stood at -$1.5 million in 2022, then fell by 13.44% to -$1.6 million in 2023, then climbed by 11.1% to -$1.5 million in 2024, then tumbled by 45.5% to -$2.1 million in 2025, then dropped by 0.29% to -$2.1 million in 2026.
• The last three Common Equity figures came in at -$2.1 million (Q1 2026), -$2.1 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.